 |
GlobeImmune’s Hepatitis C Product Candidate Improves End of Treatment Response in All IL-28 B Genotypes, with the Greatest Effect in the Hardest-to-Treat Patients
[ Read Full Article | 04-16-2010 ] |
|
|
|
GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to be First Therapeutic Vaccine for HCV
[ Read Full Article | 04-15-2010 ] |
|
|
|
GlobeImmune Announces Presentations of GI-5005 Phase 2b Data at EASL 2010 Meeting
[ Read Full Article | 03-17-2010 ] |
|
|
|
GlobeImmune Announces $17.5 Million Series E Financing
[ Read Full Article | 01-19-2010 ] |
|
|
|
GlobeImmune’s Hepatitis C Therapeutic Vaccine Combined with Standard of Care Increases End of Treatment Response Rate by 15%
[ Read Full Article | 11-02-2009 ] |
|
|
|
GlobeImmune Announces Late-Breaker Presentation of GI-5005 Treatment Response Data at AASLD 2009 Meeting
[ Read Full Article | 10-06-2009 ] |
|
|
|
GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance
[ Read Full Article | 05-15-2009 ] |
|
|
|
GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 percent in Phase 2 Clinical Trial
[ Read Full Article | 04-24-2009 ] |
|
|
|
GlobeImmune Initiates Phase 1 Clinical Trial with NCI in CEA Over-expressing Cancers
[ Read Full Article | 04-16-2009 ] |
|
|
|
GlobeImmune Hepatitis C Therapeutic Vaccine, GI-5005, Doubles Viral Clearance and Increases RVR Rates in Phase 2 Clinical Trial
[ Read Full Article | 11-01-2008 ] |
|
|
|
GlobeImmune HCV Phase 2 Four-week Clinical Trial Data for GI-5005 to be Highlighted at the AASLD President's Press Conference
[ Read Full Article | 10-28-2008 ] |
|
|
|
GlobeImmune Announces Late-Breaker Presentation of Interim Efficacy and Safety Data for GI-5005 at AASLD 2008 Meeting
[ Read Full Article | 09-24-2008 ] |
|
|
|
GlobeImmune Signs CRADA with the National Institutes of Health to Develop Cancer Therapeutics
[ Read Full Article | 07-09-2008 ] |
|
|
|
FierceBiotech Names GlobeImmune as One of the Fierce 15
[ Read Full Article | 06-24-2008 ] |
|
|
|
GlobeImmune Announces Completion of Planned Enrollment for GI-5005-02 Phase 2 Trial
[ Read Full Article | 05-20-2008 ] |
|
|
|
GlobeImmune Announces Appointment of J. William Freytag Ph.D to GlobeImmune Board of Directors
[ Read Full Article | 03-25-2008 ] |
|
|
|
GlobeImmune Announces Initiation of a Phase 2a Clinical Trial of GI-4000 in Patients with Non-Small Cell Lung Cancer at Memorial Sloan Kettering
[ Read Full Article | 03-19-2008 ] |
|
|
|
GlobeImmune to Present at the JPMorgan Healthcare Conference
[ Read Full Article | 01-03-2008 ] |
|
|
|
GlobeImmune Announces Initiation of Phase 2 Clinical Trial of GI-5005 in Patients with Chronic Hepatitis C
[ Read Full Article | 12-19-2007 ] |
|
|
|
GlobeImmune Announces Presentation of Results from a Randomized Phase 1b Study of the GI-5005 Tarmogen in Patients with Chronic Hepatitis C Infection
[ Read Full Article | 11-06-2007 ] |
|
|
|
GlobeImmune Announces Presentation of Additional Phase 1b Hepatitis C Results at American Association for the Study of Liver Diseases 2007 Annual Meeting
[ Read Full Article | 11-01-2007 ] |
|
|
|
GlobeImmune Announces Presentation of Pre-Clinical Data on GI-10001 for Chronic Myelogenous Leukemia
[ Read Full Article | 10-25-2007 ] |
|
|
|
GlobeImmune Raises $41.2 Million In Series C Financing
[ Read Full Article | 09-26-2007 ] |
|
|
|
GlobeImmune Updates Speaking Date and Time at the JPMorgan Healthcare Conference
[ Read Full Article | 01-05-2007 ] |
|
|
|
GlobeImmune Announces Presentation of Positive Interim Results from a Study of the GI-5005 Tarmogen in Patients with Chronic Hepatitis C Infection
[ Read Full Article | 10-27-2006 ] |
|
|
|
GlobeImmune Announces GI-5005 Tarmogen Data for Chronic Hepatitis C Infection to be Presented at the American Association for the Study of Liver Diseases (AASLD)
[ Read Full Article | 10-17-2006 ] |
|
|
|
GlobeImmune Appoints John Frenz Vice President of Operations
[ Read Full Article | 08-28-2006 ] |
|
|
|
Dr. Jules Harris Joins GlobeImmune Scientific Advisory Board
[ Read Full Article | 08-09-2006 ] |
|
|
|
GlobeImmune Initiates Phase 2 Trial for Pancreas Cancer
[ Read Full Article | 06-08-2006 ] |
|
|
|
GlobeImmune Adds Jeffrey Rona to Executive Management Team
[ Read Full Article | 05-15-2006 ] |
|
|
|
GlobeImmune secures additional $4.1 million and closes Series B financing with a total of $38.4 million raised
[ Read Full Article | 01-10-2006 ] |
|
|
|
Globelmmune Raises Over $34 Million in Series B Financing
[ Read Full Article | 09-14-2005 ] |
|
|
|
GlobeImmune Appoints Carl June, M.D. to Scientific Advisory Board
[ Read Full Article | 08-31-2005 ] |
|
|
|
GlobeImmune Appoints Francis V. Chisari, M.D. to Scientific Advisory Board
[ Read Full Article | 08-03-2005 ] |
|
|
|
GlobeImmune Initiates Phase 1b Study of GI-5005 for Chronic Hepatitis C Infection
[ Read Full Article | 07-26-2005 ] |
|
|
|
GlobeImmune and MycoLogics Enter Tarmogen Technlogy Collaboration for Antifungal Therapeutics
[ Read Full Article | 01-17-2005 ] |
|
|
|
GlobeImmune Appoints Paul Bunn, M.D. To Scientific Advisory Board
[ Read Full Article | 09-13-2004 ] |
|
|
|
GlobeImmune Prepares to Initiate Phase 1 Clinical Trial for GI-4000 Cancer Immunotherapy
[ Read Full Article | 05-25-2004 ] |
|
|
|
GlobeImmune Announces Appointment of Scientific Advisory Board Members
[ Read Full Article | 05-13-2004 ] |
|
|
|
GlobeImmune Announces Appointment of Alex Franzusoff, Ph.D. as VP of Research
[ Read Full Article | 12-19-2003 ] |
|
|
|
GlobeImmune Announces Closing Of Series A Financing Of $8 Million
[ Read Full Article | 06-18-2003 ] |
|
|
|
|
|
